Galectin-3—Insights from Inflammatory Bowel Disease and Primary Sclerosing Cholangitis
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26136101 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Thomas Grewal und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, NSW 2006, Australia. Hauptthemen laut MEDLINE: Cholangitis, Sclerosing, Inflammatory Bowel Diseases, Galectin 3. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 185 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Inflammatory bowel disease (IBD) and primary sclerosing cholangitis (PSC) are related diseases with poorly understood pathophysiology. While therapy options for IBD have increased, treatment options for PSC remain limited. Galectin-3 is a multifunctional lectin expressed in intestinal epithelial cells, and is abundant in immune cells such as macrophages, with roles in cell adhesion, apoptosis, inflammation and fibrosis being associated with IBD and PSC disease development and progression. In addition, galectin-3 is also a visceral fat-derived protein whose systemic levels are increased in obese individuals, the latter correlating with a poorer prognosis in IBD and PSC patients. On the other hand, decreased galectin-3 expression in the inflamed mucosal tissues of mice and patients with IBD possibly indicate a protective role of this lectin in IBD. However, galectin-3 loss or inhibition is protective in most animal models of liver fibrosis but exacerbates the severity of autoimmune liver disease. Hence, with PSC being a slowly progressing autoimmune hepatobiliary disease closely related to IBD, further studies evaluating galectin-3 as a therapeutic target or biomarker for the severity of IBD and the occurrence of PSC are still needed. This review summarizes studies that have analyzed expression patterns and functions of galectin-3 in IBD and PSC. Current evidence suggests that strategies to block galectin-3 are not advised for patients with IBD and PSC-IBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, NSW 2006, Australia.
- Department of Internal Medicine I, University Hospital Regensburg, 93053 Regensburg, Germany.
ORCID-Profile: Thomas Grewal, Christa Buechler
Zitieren
APA
Grewal, T., Tews, H. C., & Buechler, C. (2025). Galectin-3—Insights from Inflammatory Bowel Disease and Primary Sclerosing Cholangitis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26136101
Vancouver
Grewal T, Tews HC, Buechler C. Galectin-3—Insights from Inflammatory Bowel Disease and Primary Sclerosing Cholangitis. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26136101
BibTeX
@article{Grewal2025,
author = {Grewal, Thomas and Tews, Hauke Christian and Buechler, Christa},
title = {Galectin-3—Insights from Inflammatory Bowel Disease and Primary Sclerosing Cholangitis},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26136101}
}
EUVIMED